MX2015014199A - Moduladores del receptor de progesterona para usarse en la terapia de fibromas uterinos. - Google Patents

Moduladores del receptor de progesterona para usarse en la terapia de fibromas uterinos.

Info

Publication number
MX2015014199A
MX2015014199A MX2015014199A MX2015014199A MX2015014199A MX 2015014199 A MX2015014199 A MX 2015014199A MX 2015014199 A MX2015014199 A MX 2015014199A MX 2015014199 A MX2015014199 A MX 2015014199A MX 2015014199 A MX2015014199 A MX 2015014199A
Authority
MX
Mexico
Prior art keywords
uterine fibroids
therapy
receptor modulators
progesteron receptor
relates
Prior art date
Application number
MX2015014199A
Other languages
English (en)
Inventor
Ian Osterloh
Elke Bestel
Ernest Loumaye
Annie Dacquin
Florence Jean
Original Assignee
Preglem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preglem Sa filed Critical Preglem Sa
Publication of MX2015014199A publication Critical patent/MX2015014199A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K9/00—Screening of apparatus or components against electric or magnetic fields
    • H05K9/0007—Casings
    • H05K9/0052—Shielding other than Faraday cages

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Power Engineering (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Percussion Or Vibration Massage (AREA)

Abstract

La presente invención se refiere a una terapia a largo plazo que incluye cursos de tratamiento repetidos con acetato de ulipristal o cualquiera de sus metabolitos para tratar los fibromas uterinos. La presente invención también se refiere a una terapia combinada que aplica acetato de ulipristal con progestina con el fin de mejorar el tratamiento actualmente usado para los fibromas uterinos.
MX2015014199A 2013-04-10 2014-04-09 Moduladores del receptor de progesterona para usarse en la terapia de fibromas uterinos. MX2015014199A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1300211 2013-04-10
PCT/IB2014/060558 WO2014167510A2 (en) 2013-04-10 2014-04-09 Progesteron receptor modulators for use in the therapy of uterine fibroids

Publications (1)

Publication Number Publication Date
MX2015014199A true MX2015014199A (es) 2016-06-21

Family

ID=89707373

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014199A MX2015014199A (es) 2013-04-10 2014-04-09 Moduladores del receptor de progesterona para usarse en la terapia de fibromas uterinos.

Country Status (19)

Country Link
US (2) US10172869B2 (es)
EP (1) EP2983672A2 (es)
JP (1) JP2016516764A (es)
KR (1) KR20150139919A (es)
CN (1) CN105120874A (es)
AR (1) AR095831A1 (es)
AU (1) AU2014252196B2 (es)
BR (1) BR112015025954A2 (es)
CA (1) CA2907674A1 (es)
EA (1) EA030831B1 (es)
HK (1) HK1221169A1 (es)
IL (1) IL241380B (es)
MX (1) MX2015014199A (es)
MY (1) MY181448A (es)
NZ (1) NZ712984A (es)
SG (1) SG11201507260QA (es)
UY (1) UY35528A (es)
WO (1) WO2014167510A2 (es)
ZA (1) ZA201507535B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113797210A (zh) * 2015-05-18 2021-12-17 拜耳医药股份有限公司 选择性孕酮受体调节剂(sprm)方案
CN118436663A (zh) * 2024-04-25 2024-08-06 浙江大学 醋酸乌利司他在制备抗纤维化药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
US4155991A (en) 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US3991760A (en) 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US4286587A (en) 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4250611A (en) 1979-04-19 1981-02-17 Alza Corporation Process for making drug delivery device with reservoir
US4596576A (en) 1984-10-12 1986-06-24 Akzo N.V. Release system for two or more active substances
NL8500470A (nl) 1985-02-19 1986-09-16 Achel Homesteel Pvba Intravaginaal orgaan.
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FI95768C (fi) 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
EP1613640A4 (en) 2003-02-28 2010-05-19 Us Gov Health & Human Serv PROCESS FOR PREPARING 17 ALPHA-ACETOXY-11 BETA- (4-N, N-DIMETHYLAMINOPHENYL) -19-NORPREGNA-4,9-DIENE-3,20-DION, INTERMEDIATE PRODUCTS AND METHOD OF MANUFACTURING THESE INTERMEDIATE PRODUCTS
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
US20050215536A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/ progestin treatment
BRPI0513141A (pt) 2004-07-09 2008-04-29 Population Council Inc composição para anel vaginal, e, processo de contracepção a longo prazo
WO2007103510A2 (en) 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
EP3693376A1 (en) 2006-10-24 2020-08-12 Allergan Pharmaceuticals International Limited Compositions for suppressing endometrial proliferation
MX2009006912A (es) 2006-12-28 2009-08-12 Repros Therapeutics Inc Metodos y formulaciones para biodisponibilidad mejorada de antiprogestinas.
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
CN102727457B (zh) * 2011-04-08 2014-05-28 华润紫竹药业有限公司 稳定的醋酸优力司特制剂

Also Published As

Publication number Publication date
MY181448A (en) 2020-12-22
AR095831A1 (es) 2015-11-11
ZA201507535B (en) 2017-02-22
HK1221169A1 (zh) 2017-05-26
UY35528A (es) 2014-09-30
US20160038510A1 (en) 2016-02-11
IL241380B (en) 2018-11-29
EA201591892A1 (ru) 2016-02-29
CA2907674A1 (en) 2014-10-16
AU2014252196A1 (en) 2015-10-29
JP2016516764A (ja) 2016-06-09
AU2014252196B2 (en) 2019-05-16
WO2014167510A2 (en) 2014-10-16
EA030831B1 (ru) 2018-10-31
US10172869B2 (en) 2019-01-08
KR20150139919A (ko) 2015-12-14
IL241380A0 (en) 2015-11-30
SG11201507260QA (en) 2015-10-29
BR112015025954A2 (pt) 2017-07-25
US20190262361A1 (en) 2019-08-29
EP2983672A2 (en) 2016-02-17
WO2014167510A3 (en) 2015-02-19
CN105120874A (zh) 2015-12-02
NZ712984A (en) 2020-07-31

Similar Documents

Publication Publication Date Title
HK1219060A1 (zh) 用於治療疼痛的鈉通道調節劑
HK1221408A1 (zh) 用於治療成膠質細胞瘤的組合療法
LT3498725T (lt) Steroidas su 19-nor c3,3-dipakeistuoju c21-n-pirazolilu, skirtas naudoti terapijoje
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
ZA201702410B (en) Sodium channel modulators for the treatment of pain and diabetes
MX2016002574A (es) Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
IL238907A0 (en) A device for treating depression, anxiety and pain
EP2952149A4 (en) THERAPEUTIC TREATMENT DEVICE
SA516370641B1 (ar) مركبات حلقية غير متجانسة وطرق لاستخدامها
MX2015017863A (es) Moduladores de receptor de hormona de crecimiento.
IL245483A0 (en) Fibroblast growth factor receptor 3 (fgfr3) compounds and medical uses
DK201300055U4 (da) Tæppe med kanaler fyldt med i det væsentlige sfæriske objekter til terapeutisk behandling
EP3033350A4 (en) Progesterone phosphate analogs and uses related thereto
NZ712984A (en) Progesteron receptor modulators for use in the therapy of uterine fibroids
EP2952150A4 (en) DEVICE FOR THERAPEUTIC TREATMENT AND CONTROL METHOD THEREFOR
EA201491939A1 (ru) Модуляторы прогестероновых рецепторов для применения в профилактике или лечении болезней, опосредованных андрогенами
ITTO20130099U1 (it) Benda elastica, particolarmente per l'impiego nel trattamento dell'edema da insufficienza veno-linfatica
ITTO20130512A1 (it) Benda elastica, particolarmente per l'impiego nel trattamento dell'edema da insufficienza veno-linfatica
IN2013MU02732A (es)
UA91089U (uk) Застосування препарату "біоглобін-у" як препарату для корекції гіпотиреоїдних станів в експерименті
UA81387U (ru) Способ лечения ожирения и избыточной массы тела методом ворошилова-довгого
UA84296U (ru) Способ лечения эпидемического паротита у взрослых
TWD159206S (zh) 電位治療裝置用電壓產生器
AU2013904331A0 (en) Massage Therapy Device
GB201302884D0 (en) Novel methods for diagnosis and therapy